Why did Corteva's Q3 Seed sales jump so much, and is that growth sustainable?

Seed sales rose 33% to $917M, with volume up 27%, largely from early safrinha deliveries in Latin America, corn acre recovery in Argentina, and higher corn sales in EMEA. Price/mix rose 4%, aided by out-licensing income. Part of the quarter's gain reflects timing of deliveries pulled forward into Q3, so investors should watch whether full-year Seed growth holds, especially given lower soybean area in North America and Asia Pacific softness.

Does the Q3 operating profit improvement mean Corteva is now profitable on a GAAP basis?

Not in Q3. GAAP loss from continuing operations was $(308)M, or $(0.46) per share, though this is better than the $(519)M loss a year earlier. The gap from Operating EBITDA of $49M mainly reflects D&A of $300M (including intangible amortization), interest expense, non-operating costs, FX losses, and significant items. Operating EPS excludes amortization of intangibles and other items, so it is not directly comparable to GAAP.

What changed in the full-year 2025 guidance, and what does it imply for the rest of the year?

Corteva raised full-year guidance to Operating EBITDA of $3.8-$3.9B and Operating EPS of $3.25-$3.35. With YTD Operating EBITDA at $3.40B, the implied Q4 Operating EBITDA is roughly $0.4-$0.5B, which is above the Q4 2024 level. The raise reflects YTD volume gains, controllable levers, and growth platforms. Guidance excludes the impact of significant items and cannot be reconciled to GAAP without unreasonable effort.

What is the separation, and how will it affect shareholders?

On October 1, 2025, Corteva announced plans to split into New Corteva (crop protection, including biologicals) and SpinCo (advanced genetics, gene editing, hybrid wheat, biofuels). The transaction is expected to be completed in the second half of 2026, subject to customary approvals, and is intended to be tax-free for U.S. federal purposes. Both companies would target investment-grade credit ratings. Leadership and board transition planning is ongoing, and execution risk includes costs, management distraction, and litigation.

Are there any concerns in the cash flow or balance sheet that investors should watch?

Yes. Cash from continuing operations was negative $(941)M YTD, versus $(1,871)M a year earlier, due to a $1.66B increase in receivables and a $2.82B decline in deferred revenue. Receivables rose to $7.78B from $5.68B at year-end 2024, and short-term borrowings increased to $2.69B. Cash fell to $2.51B. These are seasonal patterns, but they should be monitored alongside the planned $1.0B of 2025 buybacks and the separation costs.

CTVA 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed November 4, 2025. Cited figures are marked; the original filing is the authoritative source.

Corteva (CTVA) reported third-quarter 2025 results that were strong on the top line and a sharp improvement in profitability versus the prior year, and it raised its full-year 2025 guidance.

Q3 net sales rose 13% to $2.62 billion^a (11% organic), driven by a 12% volume increase, with Seed sales up 33% on early Latin American safrinha deliveries and corn gains. Operating EBITDA swung to $49 million from a $(100) million loss a year earlier, and Operating EPS was $(0.23) versus $(0.49). GAAP results remained negative for the quarter, with a loss from continuing operations of $(308) million, or $(0.46) per share, though this was an improvement from the prior-year loss of $(519) million.

Year-to-date, net sales were $13.49 billion^b (+4%, +6% organic), GAAP EPS from continuing operations was $2.54, and Operating EPS was $3.11 (+39%). Management raised 2025 guidance to net sales of $17.7-$17.9 billion, Operating EBITDA of $3.8-$3.9 billion, and Operating EPS of $3.25-$3.35. The company also gave a preliminary 2026 Operating EBITDA midpoint of $4.1 billion, implying roughly 6% growth.

Guidance was credited to year-to-date volume gains, controllable cost levers, and growth in new technology, biologicals, and out-licensing. The company expects to repurchase about $1.0 billion^c of shares in 2025. The most important strategic item is the planned separation into two independent public companies, announced October 1, 2025: "New Corteva," focused on crop protection including biologicals, and "SpinCo," focused on advanced genetics, gene editing, hybrid wheat, and biofuels.

The separation is expected in the second half of 2026 and is intended to be tax-free. Investors should note that quality-of-earnings items remain: a $(308) million GAAP Q3 loss, $(0.13) per share of YTD discontinued operations losses, and a seasonal working capital build in receivables and cash flow from operations that was negative YTD.

02—Key points

Key Highlights

Q3 2025 net sales rose 13% to $2.62B (11% organic), with volume up 12% and price/mix down 1%; Seed sales grew 33% to $917M and Crop Protection sales grew 4% to $1.70B.
Q3 Operating EBITDA was $49M versus $(100)M a year ago, and Operating EPS improved to $(0.23) from $(0.49); GAAP loss from continuing operations narrowed to $(308)M from $(519)M.
YTD 2025 Operating EBITDA reached $3.40B (+19%) and Operating EPS reached $3.11 (+39%), with GAAP EPS from continuing operations at $2.54 versus $1.29.
Full-year 2025 guidance was raised: net sales $17.7-$17.9B, Operating EBITDA $3.8-$3.9B, and Operating EPS $3.25-$3.35, driven by YTD performance and controllable cost benefits.
Preliminary 2026 Operating EBITDA midpoint of $4.1B implies about 6% growth over 2025's expected midpoint.
Planned separation into "New Corteva" (crop protection and biologicals) and "SpinCo" (genetics, gene editing, hybrid wheat, biofuels) is expected in 2H 2026 and intended to be tax-free.
Capital returns continue with about $1.0B of share repurchases expected in 2025, while YTD cash from operations from continuing operations was negative $(941)M due to seasonal working capital and deferred revenue unwinds.

03—Questions

Frequently Asked Questions

Why did Corteva's Q3 Seed sales jump so much, and is that growth sustainable?
Seed sales rose 33% to $917M, with volume up 27%, largely from early safrinha deliveries in Latin America, corn acre recovery in Argentina, and higher corn sales in EMEA. Price/mix rose 4%, aided by out-licensing income. Part of the quarter's gain reflects timing of deliveries pulled forward into Q3, so investors should watch whether full-year Seed growth holds, especially given lower soybean area in North America and Asia Pacific softness.
Does the Q3 operating profit improvement mean Corteva is now profitable on a GAAP basis?
Not in Q3. GAAP loss from continuing operations was $(308)M, or $(0.46) per share, though this is better than the $(519)M loss a year earlier. The gap from Operating EBITDA of $49M mainly reflects D&A of $300M (including intangible amortization), interest expense, non-operating costs, FX losses, and significant items. Operating EPS excludes amortization of intangibles and other items, so it is not directly comparable to GAAP.
What changed in the full-year 2025 guidance, and what does it imply for the rest of the year?
Corteva raised full-year guidance to Operating EBITDA of $3.8-$3.9B and Operating EPS of $3.25-$3.35. With YTD Operating EBITDA at $3.40B, the implied Q4 Operating EBITDA is roughly $0.4-$0.5B, which is above the Q4 2024 level. The raise reflects YTD volume gains, controllable levers, and growth platforms. Guidance excludes the impact of significant items and cannot be reconciled to GAAP without unreasonable effort.
What is the separation, and how will it affect shareholders?
On October 1, 2025, Corteva announced plans to split into New Corteva (crop protection, including biologicals) and SpinCo (advanced genetics, gene editing, hybrid wheat, biofuels). The transaction is expected to be completed in the second half of 2026, subject to customary approvals, and is intended to be tax-free for U.S. federal purposes. Both companies would target investment-grade credit ratings. Leadership and board transition planning is ongoing, and execution risk includes costs, management distraction, and litigation.
Are there any concerns in the cash flow or balance sheet that investors should watch?
Yes. Cash from continuing operations was negative $(941)M YTD, versus $(1,871)M a year earlier, due to a $1.66B increase in receivables and a $2.82B decline in deferred revenue. Receivables rose to $7.78B from $5.68B at year-end 2024, and short-term borrowings increased to $2.69B. Cash fell to $2.51B. These are seasonal patterns, but they should be monitored alongside the planned $1.0B of 2025 buybacks and the separation costs.

04—Continue

← View all 8-K filings